Telehealth provider Teladoc Q3 revenue beats estimates

Teladoc Health

29/10/2025 20:36

Overview

Teladoc Q3 2025 revenue down 2% yr/yr, beats analyst expectations

Adjusted EBITDA for Q3 2025 beats analyst expectations, despite a 16% yr/yr decline

Company reports Q3 net loss of $49.5 mln, impacted by goodwill impairment charge

Outlook

Teladoc expects 4Q 2025 revenue between $622 mln and $652 mln

Company forecasts full-year 2025 revenue of $2.510 bln to $2.539 bln

Teladoc anticipates full-year 2025 net loss per share of ($1.25) to ($1.10)

Company sees BetterHelp 4Q 2025 revenue growth decline of (8.8%) to (3.8%)

Result Drivers

INTEGRATED CARE GROWTH - Integrated Care segment revenue increased 2% yr/yr, driven by strategic initiatives

BETTERHELP DECLINE - BetterHelp segment revenue decreased 8% yr/yr, attributed to market conditions

GOODWILL IMPAIRMENT - Goodwill impairment charge of $12.6 mln impacted net income, related to Integrated Care segment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$626.43 mln
$626 mln (23 Analysts)
Q3 EPS
-$0.28
Q3 Net Income
-$49.50 mln
Q3 Adjusted EBITDA
Beat
$69.90 mln
$65.90 mln (22 Analysts)
Q3 Basic EPS
-$0.28


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 21 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Teladoc Health Inc is $9.00, about 7.1% above its October 28 closing price of $8.36

Press Release: ID:nGNXJkxpH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)